Seamac India Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 18-12-2024
- Paid Up Capital ₹ 0.44 M
as on 18-12-2024
- Company Age 30 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.22 M
as on 18-12-2024
- Revenue 13.79%
(FY 2020)
- Profit -35.52%
(FY 2020)
- Ebitda -978.16%
(FY 2020)
- Net Worth 7.56%
(FY 2020)
- Total Assets 50.43%
(FY 2020)
About Seamac India Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.44 M.
The company currently has active open charges totaling ₹5.22 M.
Sudhir Sharma and Abhishek Sharma serve as directors at the Company.
- CIN/LLPIN
U74899DL1994PTC059752
- Company No.
059752
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jun 1994
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Seamac India Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudhir Sharma  | Managing Director | 22-Jun-1994 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Abhishek Sharma | Director | 20-Mar-2018 | Current |
Financial Performance of Seamac India Pharmaceuticals.
Seamac India Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 13.79% increase. The company also saw a substantial fall in profitability, with a 35.52% decrease in profit. The company's net worth moved up by a moderate rise of 7.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Seamac India Pharmaceuticals?
In 2019, Seamac India Pharmaceuticals had a promoter holding of 99.66% and a public holding of 0.34%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Seamac Formulations Private LimitedActive 17 years 11 monthsSudhir Sharma and Abhishek Sharma are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 Jun 2020 | ₹0.64 M | Open |
Others Creation Date: 21 Aug 1999 | ₹3.20 M | Open |
Hrryana Financial Corp. Creation Date: 24 Nov 1994 | ₹1.38 M | Open |
How Many Employees Work at Seamac India Pharmaceuticals?
Unlock and access historical data on people associated with Seamac India Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Seamac India Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Seamac India Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
